Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

neurorecovery

Artificial intelligence firm licenses Janssen candidates for development

UK-based BenevolentAI aims to move them into late-stage trials by mid-2017

- PMLiVE

Boehringer Ingelheim launches AI-powered animal health website

The new site uses ‘machine learning’ to tailor content to users’ requirements

Boehringer Ingelheim headquarters

Boehringer crowdsources psychiatric research team

Collaboration with BioMed X aims to identify new treatment approaches

Biogen Idec building

Biogen plans spin-out of haemophilia business

Aims to create two 'agile' specialist firms

EISAI

Eisai establishes neuroscience unit in Belgium and Luxembourg

Follows the company's recent expansion in Australia

- PMLiVE

Biogen Idec appoints senior neuroscientists

Christopher Henderson and Richard Ransohoff make the move from academia

- PMLiVE

Interview: Mike Hutton, Lilly

Lilly’s chief scientific officer for neurodegenerative diseases talks about his hopes for Alzheimer’s research and making the move from academia to pharma

Bristol-Myers Squibb (BMS) building

BMS exits hep C, diabetes and neuroscience drug discovery

Will discontinue 'broad-based discovery work' in the therapy areas

- PMLiVE

UCB signs research deal for novel neuroscience drugs

Partners with structural biology company ConfometRx

EU funds ‘human brain’ computing project

Project could ultimately help develop personalised neurological treatments

Lilly drops touted Zyprexa successor for use in schizophrenia

Pomaglumetad methionil disappoints in phase III

- PMLiVE

Interview: Jan Lundberg, Eli Lilly

We talk to Jan Lundberg, executive VP, science and technology, and president, Lilly Research Laboratories

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links